Charles River Laboratories International Inc. Common Stock (CRL)
Stock · NYSE · Health Care
$300.23as of 10/16/2026
Price chart
Active signals
CRL Signal Track Record
How signals performed across all stocks →What CRL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | -2.2% | 42% | October 6, 2026 |
| Bollinger Band Breakout | 23 | -3.0% | 48% | October 5, 2026 |
| Bollinger Band Breakdown | 20 | +1.5% | 60% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -5.0% | 33% | June 2, 2026 |
| Any 20-session window (baseline) | -0.2% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 18,300
- Website
- www.criver.com/
Fundamentals
- 1-day range
- $295.51$308.27
- Market cap
- $12.79B
- P/E (trailing)
- —
- P/E (forward)
- 24.13
- EPS (trailing)
- $-4.85
- Dividend yield
- —
- Beta
- 1.38
- Avg. volume
- 945.3K
How Charles River Laboratories International Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
Charles River Laboratories International Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CRLCharles River Laboratories International Inc. Common Stock$300.15▼ 1.99%Market cap $12.79BP/E —$146.2$333.3
- ICLRICON plc Ordinary Shares$170.18▼ 2.83%Market cap $12.34BP/E 190.41$66.57$203.91
- MEDPMedpace Holdings Inc. Common Stock$618.47▼ 1.61%Market cap $16.33BP/E 35.88$373$677.9
- INCYIncyte Corp. Common Stock$113.07▼ 0.18%Market cap $24.00BP/E 14.30$84.02$132.6
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
- OABIOmniAb Inc. Common Stock$4.59▼ 2.96%Market cap $324.74MP/E —$1.3$5.43
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRL Charles River Laboratories International Inc. Common Stock | $12.79B | — | $300.15 | ▼ 1.99% | $146.2$333.3 |
| ICLR ICON plc Ordinary Shares | $12.34B | 190.41 | $170.18 | ▼ 2.83% | $66.57$203.91 |
| MEDP Medpace Holdings Inc. Common Stock | $16.33B | 35.88 | $618.47 | ▼ 1.61% | $373$677.9 |
| INCY Incyte Corp. Common Stock | $24.00B | 14.30 | $113.07 | ▼ 0.18% | $84.02$132.6 |
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
| OABI OmniAb Inc. Common Stock | $324.74M | — | $4.59 | ▼ 2.96% | $1.3$5.43 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Here’s How Much You Would Have Made Owning Charles River Stock In The Last 20 Yearsbenzinga · 10/14/2026
- Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference CallYahoo · 10/9/2026
- Stay informed with the top movers within the S&P500 index on Thursday.ChartMill · 10/8/2026
- PGNY or CRL: Which Is the Better Value Stock Right Now?Yahoo · 10/7/2026
- Charles River Gains 75.8% in a Year: What's Driving the Rally?Yahoo · 10/7/2026
- Is It Prudent to Add Teleflex Stock to Your Portfolio Now?Yahoo · 10/6/2026
- Charles River and Autolomous Partner to Transform Laboratory Execution SystemsYahoo · 10/6/2026
- Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE IntegrationBenzinga · 10/6/2026
- Uncover the latest developments among S&P500 stocks in today's session.ChartMill · 10/5/2026
Insider Activity
Insider Actions →- Shannon M. Parisotto · October 5, 2026 · Option Exercise981 @ $208.44
- Shannon M. Parisotto · October 5, 2026 · Sale981 @ $308.44
- Glenn Coleman · September 30, 2026 · Buy10 @ $297.43
- James C. Foster · August 25, 2026 · Option Exercise12.4K @ $208.44
- James C. Foster · August 25, 2026 · Option Exercise21.1K @ $194.12
- James C. Foster · August 25, 2026 · Sale33.6K @ $300
- Birgit Girshick · August 19, 2026 · Gift528
- Shannon M. Parisotto · August 19, 2026 · Option Exercise2.0K @ $194.12
- Shannon M. Parisotto · August 19, 2026 · Sale2.0K @ $294.12
- Nancy C. Andrews · August 18, 2026 · Option Exercise573 @ $164.3
- Nancy C. Andrews · August 18, 2026 · Sale573 @ $285.24
- Birgit Girshick · August 11, 2026 · Option Exercise6.5K @ $179.66
- Birgit Girshick · August 11, 2026 · Sale6.5K @ $279.9
- Shannon M. Parisotto · August 11, 2026 · Option Exercise3.7K @ $179.66
- Shannon M. Parisotto · August 11, 2026 · Sale3.7K @ $279.66
Institutional Ownership
March 31, 2026
- Total shares held
- 54.48M
- Total value held
- $8.91B
- Institutional holders
- 550
- Unknown3.86M
- Unknown3.46M
- Unknown3.20M
- Unknown2.40M
- Unknown2.15M
- Unknown1.99M
- Unknown1.87M
- Unknown1.65M
- Unknown1.63M
- Unknown1.44M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage
Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.